FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034693832> ?p ?o ?g. }

• W2034693832 endingPage "234" @default.
• W2034693832 startingPage "228" @default.
• W2034693832 abstract "Bevacizumab with chemotherapy improves outcomes in patients with metastatic breast cancer (MBC). The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast cancer (LABC).Between November 2006 and August 2007, 45 women with HER2(-) LABC began preoperative standard AC (doxorubicin [Adriamycin], cyclophosphamide) × 4 cycles followed by docetaxel 75 mg/m(2) intravenously (I.V.) on day 1 and capecitabine 825 mg/m(2) twice daily on days 1-14 (TX, docetaxel [Taxotere] and capecitabine [Xeloda]) every 21 days for 4 cycles. Bevacizumab 15 mg/kg I.V. was given concurrently with chemotherapy every 21 days for a total of 6 preoperative doses. Postoperatively bevacizumab was resumed for a total of 10 doses. The primary endpoint was pathologic complete response (pCR) in the breast.Thirty patients (66.7%) had stage IIIA disease, 12 (26.7%) patients had stage IIIB, and 3 patients (6.7%) had stage IIIC. Of these, 10 (22%) had inflammatory breast cancer (IBC), and 27 (60%) had estrogen receptor (ER)(+) disease. A pCR in the breast with negative axillary nodes was documented in 4 (9%) of 45 patients. Toxicities that were seen with AC and bevacizumab included fatigue (grade 2/3; 31% and 9%, respectively), mucositis (grade 2/3; 29% and 2%, respectively), and headache (grade 2/3; 16% and 7%, respectively). Toxicities seen with TX and bevacizumab included mucositis (grade 2/3; 48% and 25%, respectively), fatigue (grade 2/3; 43% and 18%, respectively), and hand-foot syndrome (grade 2/3; 34% and 23%, respectively).This regimen demonstrated only modest activity with substantial toxicity and does not appear to warrant further evaluation." @default.
• W2034693832 created "2016-06-24" @default.
• W2034693832 creator A5002068827 @default.
• W2034693832 creator A5009523391 @default.
• W2034693832 creator A5025127002 @default.
• W2034693832 creator A5043776379 @default.
• W2034693832 creator A5049175137 @default.
• W2034693832 creator A5049493074 @default.
• W2034693832 creator A5055013606 @default.
• W2034693832 creator A5063504632 @default.
• W2034693832 creator A5064040768 @default.
• W2034693832 creator A5067203408 @default.
• W2034693832 creator A5083386276 @default.
• W2034693832 creator A5085165458 @default.
• W2034693832 creator A5085474533 @default.
• W2034693832 creator A5090117259 @default.
• W2034693832 date "2011-08-01" @default.
• W2034693832 modified "2023-10-01" @default.
• W2034693832 title "Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group" @default.
• W2034693832 cites W2009615948 @default.
• W2034693832 cites W2034729689 @default.
• W2034693832 cites W2061094294 @default.
• W2034693832 cites W2103563357 @default.
• W2034693832 cites W2117188579 @default.
• W2034693832 cites W2126275851 @default.
• W2034693832 cites W2130771089 @default.
• W2034693832 cites W2139248078 @default.
• W2034693832 cites W2156728978 @default.
• W2034693832 cites W2162352067 @default.
• W2034693832 cites W2167224460 @default.
• W2034693832 doi "https://doi.org/10.1016/j.clbc.2011.04.001" @default.
• W2034693832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21684812" @default.
• W2034693832 hasPublicationYear "2011" @default.
• W2034693832 type Work @default.
• W2034693832 sameAs 2034693832 @default.
• W2034693832 citedByCount "19" @default.
• W2034693832 countsByYear W20346938322012 @default.
• W2034693832 countsByYear W20346938322013 @default.
• W2034693832 countsByYear W20346938322014 @default.
• W2034693832 countsByYear W20346938322015 @default.
• W2034693832 countsByYear W20346938322016 @default.
• W2034693832 countsByYear W20346938322019 @default.
• W2034693832 countsByYear W20346938322022 @default.
• W2034693832 crossrefType "journal-article" @default.
• W2034693832 hasAuthorship W2034693832A5002068827 @default.
• W2034693832 hasAuthorship W2034693832A5009523391 @default.
• W2034693832 hasAuthorship W2034693832A5025127002 @default.
• W2034693832 hasAuthorship W2034693832A5043776379 @default.
• W2034693832 hasAuthorship W2034693832A5049175137 @default.
• W2034693832 hasAuthorship W2034693832A5049493074 @default.
• W2034693832 hasAuthorship W2034693832A5055013606 @default.
• W2034693832 hasAuthorship W2034693832A5063504632 @default.
• W2034693832 hasAuthorship W2034693832A5064040768 @default.
• W2034693832 hasAuthorship W2034693832A5067203408 @default.
• W2034693832 hasAuthorship W2034693832A5083386276 @default.
• W2034693832 hasAuthorship W2034693832A5085165458 @default.
• W2034693832 hasAuthorship W2034693832A5085474533 @default.
• W2034693832 hasAuthorship W2034693832A5090117259 @default.
• W2034693832 hasConcept C121608353 @default.
• W2034693832 hasConcept C126322002 @default.
• W2034693832 hasConcept C141071460 @default.
• W2034693832 hasConcept C143998085 @default.
• W2034693832 hasConcept C2775930923 @default.
• W2034693832 hasConcept C2776694085 @default.
• W2034693832 hasConcept C2776755627 @default.
• W2034693832 hasConcept C2777802072 @default.
• W2034693832 hasConcept C2777909004 @default.
• W2034693832 hasConcept C2778496288 @default.
• W2034693832 hasConcept C2781190966 @default.
• W2034693832 hasConcept C2781413609 @default.
• W2034693832 hasConcept C526805850 @default.
• W2034693832 hasConcept C530470458 @default.
• W2034693832 hasConcept C71924100 @default.
• W2034693832 hasConceptScore W2034693832C121608353 @default.
• W2034693832 hasConceptScore W2034693832C126322002 @default.
• W2034693832 hasConceptScore W2034693832C141071460 @default.
• W2034693832 hasConceptScore W2034693832C143998085 @default.
• W2034693832 hasConceptScore W2034693832C2775930923 @default.
• W2034693832 hasConceptScore W2034693832C2776694085 @default.
• W2034693832 hasConceptScore W2034693832C2776755627 @default.
• W2034693832 hasConceptScore W2034693832C2777802072 @default.
• W2034693832 hasConceptScore W2034693832C2777909004 @default.
• W2034693832 hasConceptScore W2034693832C2778496288 @default.
• W2034693832 hasConceptScore W2034693832C2781190966 @default.
• W2034693832 hasConceptScore W2034693832C2781413609 @default.
• W2034693832 hasConceptScore W2034693832C526805850 @default.
• W2034693832 hasConceptScore W2034693832C530470458 @default.
• W2034693832 hasConceptScore W2034693832C71924100 @default.
• W2034693832 hasIssue "4" @default.
• W2034693832 hasLocation W20346938321 @default.
• W2034693832 hasLocation W20346938322 @default.
• W2034693832 hasOpenAccess W2034693832 @default.
• W2034693832 hasPrimaryLocation W20346938321 @default.
• W2034693832 hasRelatedWork W1881603101 @default.
• W2034693832 hasRelatedWork W2004158172 @default.
• W2034693832 hasRelatedWork W2034693832 @default.
• W2034693832 hasRelatedWork W2073443344 @default.
• W2034693832 hasRelatedWork W2074335427 @default.

• next